International Journal of Gynecology & Obstetrics
Volume 96, Issue 3 , Pages 212-218 , March 2007

Alternatives to mifepristone for early medical abortion

  • N.L. Moreno-Ruiz

      Affiliations

    • Department of Obstetrics and Gynecology, Boston University School of Medicine, Boston MA, USA
    • Corresponding Author InformationCorresponding author. Department of Obstetrics and Gynecology, Boston University School of Medicine, 85 East Concord St, 6th Floor, Boston, MA 02118, USA. Tel.: +1 617 414 5112 (work), +1 617 459 5290 (home); fax: +1 617 414 7300.
    • ,
  • L. Borgatta

      Affiliations

    • Department of Obstetrics and Gynecology, Boston University School of Medicine, Boston MA, USA
    • ,
  • S. Yanow

      Affiliations

    • Abortion Access Project, Cambridge MA, USA
    • ,
  • N. Kapp

      Affiliations

    • Department of Obstetrics and Gynecology, Boston University School of Medicine, Boston MA, USA
    • ,
  • E.R. Wiebe

      Affiliations

    • Department of Family Practice, University of British Columbia, Vancouver, BC, Canada
    • ,
  • B. Winikoff

      Affiliations

    • Gynuity Health Projects, New York, USA

Received 30 May 2006 ,Revised 17 August 2006 ,Accepted 11 September 2006.

References 

  1. American College of Obstetricians and Gynecologists . In: Medical management of abortion. ACOG practice bulletin. Clinical management guidelines. vol. 67:Washington, DC: ACOG; 2005;
  2. Honkanen H, Piaggio G, von Hertzen H, Bártfai G, Erdenetungalag R, Gemzell-Danielssonet K, et al. WHO multinational study of three misoprostol regimens after mifepristone for early medical abortion II: side effects and women's perceptions. BJOG. 2004;111(7):715–725
  3. Kahn JG, Becher BJ, MacIsaac L, Amory JK, Neuhaus J, Olkin I, et al. The efficacy of medical abortion: a meta-analysis. Contraception. 2000;61:29–40
  4. Winikoff B, Ellertson C, Elul B, Sivin I. Acceptability and feasibility of early pregnancy termination by mifepristone-misoprostol. Arch Fam Med. 1998;7:360–365
  5. Winikoff B, Ellertson C, Clark S. Analysis of failure in medical abortion. Contraception. 1996;54:323–327
  6. Svendsen PF, Rorbye C, Vejborg T, Nilas L. Comparison of gameprost and vaginal misoprostol in first trimester mifepristone induced abortion. Contraception. 2005;72:28–32
  7. American College of Obstetricians and Gynecologists . In: Induction of labor with misoprostol. ACOG committee opinion. vol. 228:Washington, DC: ACOG; 1999;
  8. American College of Obstetricians and Gynecologists . New U.S. Food and Drug Administration Labeling on Cytotec (misoprostol) use and pregnancy. In: ACOG committee opinion on obstetric practice. vol. 283:Washington, DC: ACOG; 2003;
  9. El-Rafaey H, O'Brien P, Morafa W, Walder J, Rodeck C. Misoprostol for third stage of labour. Lancet. 1996;347:1257
  10. Goldberg A, Greenberg M, Darney P. Misoprostol and pregnancy. N Engl J Med. 2001;344(1):38–60
  11. Saxena P, Salhan S, Sarda N. Role of sublingual misoprostol for cervical ripening to vacuum aspiration in first trimester interruption of pregnancy. Contraception. 2003;67(3):213–217
  12. Carbonell JLL, Rodriguez J, Velazco A, Tanda R, Sánchez C, Barambio S, et al. Oral and vaginal misoprostol 800 mcg every 8 h for early abortion. Contraception. 2003;67:457–462
  13. Orioli IM, Castilla E. Epidemiological assessment of misoprostol teratogenicity. BJOG. 2000;107:519–523
  14. Zieman M, Fong SK, Benowitz NL, Banskter D, Darney P. Absorption kinetics of misoprostol with oral or vaginal administration. Obstet Gynecol. 1997;90:88–92
  15. Tang OS, Schweer H, Seyberth HW, Lee SW, Ho PC. Pharmacokinetics of different routes of administration of misoprostol. Human Reproduction 2002;17:332-6.
  16. Schaff EA, DiCenzo R, Fielding SL. Comparison of misoprostol plasma concentration following buccal and sublingual administration. Contraception. 2005;71:22–25
  17. Von Hertzen H, Honkanen H, Piaggio G, Bartfai G, Erdenetungalag R, Gemzell Danielsson K, et al. WHO multinational study of three misoprostol regimens after mifepristone for early medical abortion I: Efficacy. BJOG. 2003;110(9):808–818
  18. Wiebe ER, Trouton K. Comparing vaginal and buccal misoprostol when used after methotrexate for early abortion. Contraception. 2004;70:463–466
  19. Middleton T, Schaff E, Fielding SL, Scanhill M, Shannon C, Westheimer E, et al. Randomized trial of mifepristone and buccal or vaginal misoprostol for abortion through 56 days of last menstrual period. Contraception. 2005;72:328–332
  20. El-Rafaey H, Rajasekar D, Abdalla M, Calder L, Templeton A. Induction of abortion with mifepristone (RU 486) and oral or vaginal misoprostol. N Engl J Med. 1995;332:983–987
  21. Ngai SW, Tang OS, Chan YM, Ho PC. Vaginal misoprostol alone for medical abortion up to 9 weeks of gestation: efficacy and acceptability. Hum Reprod. 2000;15(5):1159–1162
  22. Gilles JM, Creinin M, Barnhart K, Westhoff C, Frederick MM, Zhang J. A randomized trial of saline solution-moistened misoprostol versus dry misoprostol for first-trimester pregnancy failure. Contraception. 2004;190:389–394
  23. Creinin MD, Carbonell J, Schwartz J, Varela L, Tanda R. A randomized trial of the effect of moistening misoprostol before vaginal administration when used with methotrexate for abortion. Contraception. 1999;5911–5916
  24. ACOG Practice Bulletin . Medical management of tubal pregnancy. In: Clinical management guidelines. vol. 3:1998;
  25. Carbonell JLL, Varela L, Velazco A, Cabezas E, Fernandez C, Sanchez C. Oral methotrexate and vaginal misoprostol for early abortion. Contraception. 1998;57:83–88
  26. Creinin M, Vittinghoff E, Schaff E, Klaisle C, Darney P, Dean C. Medical abortion with oral methotrexate and vaginal misoprostol. Obstet Gynecol. 1997;90:611–616
  27. Borgatta L, Burnhill MS, Tyson J, Leonhardt K, Hauskenecht RU, Haskell S. Early medical abortion with methotrexate and misoprostol. Obstet Gynecol. 2001;97(1):11–16
  28. Glock JL, Johnson JV, Brumsted JR. Efficacy and safety of single-dose systemic methotrexate in the treatment of ectopic pregnancy. Fertil Steril. 1994;62:716–721
  29. Carbonell-Esteve J, Varela L, Velazco A, Tanda R, Cabezas E, Sanchez C. 25 mg or 50 mg of oral methotrexate followed by vaginal misoprostol 7 days after for early abortion: a randomized trial. Gynecol Obstet Invest. 1999;47:182–187
  30. Singh K, Fong Y, Dong F. A viable alternative to surgical vacuum aspiration: repeated doses of intravaginal misoprostol over 9 hours for medical terminations of pregnancies up to 8 weeks. Br J Obstet Gynaecol. 2003;110:175–180
  31. Zikopoulos KA, Papanikolaou , Kalantaridou SN, Tsanadis GD, Plachouras NI, Dalkalitsis NA, et al. Early pregnancy termination with vaginal misoprostol before and after 42 days of gestation. Hum Reprod. 2002;17(12):3079–3083
  32. Jain JK, Dutton C, Harwood B, Mechstroth K, Mishell DR. A prospective randomized, double-blinded placebo-controlled trial comparing mifepristone to vaginal misoprostol alone for elective termination of early pregnancy. Hum Reprod. 2002;17:1477–1482
  33. Jain JK, Harwood B, Meckstroth K, Mishell D. Early pregnancy termination with vaginal misoprostol combined with loperamide and acetaminophen prophylaxis. Contraception. 2001;63:217–221
  34. Carbonell JLL, Rodriguez J, Aragon S, Velazco A, Tanda R, Sanchez C, et al. Vaginal misoprostol 1000 mcg for early abortion. Contraception. 2001;63:131–136
  35. Bugalho A, Mocumbi S, Faúndes A. Termination of pregnancies <6 weeks gestation with a single dose of 800 mcg of vaginal misoprostol. Contraception. 2000;61:47–50
  36. Velazco A, Varela L, Tanda R, Sanchez C, Barambio S, Chami S, et al. Misoprostol for abortion up to 9 weeks gestation in adolescents. Eur J Contracpt Reprod Health Care. 2000;5:227–233
  37. Carbonell-Esteve JLL, Varela L, Velazco A, Tanda R, Cabezas E, Sanchez C. Early abortion with 800 mcg of misoprostol by the vaginal route. Contraception. 1999;59:219–225
  38. Carbonell JLL, Varela L, Velazco A, Fernandez C, Sanchez C. The use of misoprostol for abortion at ≤9 weeks gestation. Eur J Contracpt Reprod Health Care. 1997;2:181–185
  39. Carbonell JLL, Varela L, Velazco A, Fernandez C. The use of misoprostol for termination of early pregnancy. Contraception. 1997;55:165–168
  40. Barbosa R, Arilha M. The Brazilian experience with cytotec. Stud Fam Plann. 1993;24:236–240
  41. Rosing MA, Archbald CD. The knowledge, acceptability and use of misoprostol for self-induced medical abortion in an urban US population. JAMWA. 2000;55(S):S183–S185
  42. Wiebe ER, Dunn S, Guilbert E, Jacot F, Lugtig L. Comparison of abortions induced by methotrexate or mifepristone followed by misoprostol. Obstet Gynecol. 2002;99:813–819
  43. Wiebe ER. Oral methotrexate compared with injected methotrexate when used with misoprostol for abortion. Am J Obstet Gynecol. 1999;181:149–152
  44. Wiebe ER. Comparing abortion induced with methotrexate and misoprostol to methotrexate alone. Contraception. 1999;59:7–10
  45. Creinin MD. Medical abortion with methotrexate 75 mg intramuscularly and vaginal misoprostol. Contraception. 1997;56:367–371
  46. Carbonell-Esteve J, Velazco A, Varela L, Cabezas E, Fernandez C, Sanchez C. Misoprostol 3, 4, or 5 days after methotrexate for early abortion. Contraception. 1997;56:169–174
  47. Creinin MD, Vittinghoff E, Keder L, Darney P, Tiller G. Methotrexate for early abortion: A multicenter trial. I. Safety and Efficacy. Contraception. 1996;53(6):321–327
  48. Wiebe ER. Abortion induced methotrexate and misoprostol. Can Med Assoc J. 1996;154(2):165–170

PII: S0020-7292(06)00446-2

doi: 10.1016/j.ijgo.2006.09.009

International Journal of Gynecology & Obstetrics
Volume 96, Issue 3 , Pages 212-218 , March 2007

Article Tools